Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Selecta Closes $15 Million Series C Financing

Abstract:
Company To Advance New Class of Synthetic Vaccines into Clinical Development based on targeted Synthetic Vaccine Particle (tSVP) platform

Selecta Closes $15 Million Series C Financing

Watertown, MA | Posted on April 5th, 2010

Selecta Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vaccines, today announced that it has raised $15 million in a Series C financing round. OrbiMed Advisors LLC led the round, with participation from existing investors Polaris Venture Partners, Flagship Ventures, NanoDimension and Leukon Investments. The Series C financing brings the total capital raised by Selecta over the past 15 months to more than $30 million.

Proceeds from the Series C financing will be used to expand Selecta's development of a new class of synthetic vaccines for prophylactic and therapeutic indications based on the company's proprietary targeted Synthetic Vaccine Particle (tSVPô) platform. The company's lead product candidate will enter first-in-human clinical evaluation in 2011. The tSVP platform is based on biodegradable polymeric nanoparticles that fully-integrate all the vaccine components for targeting to immune cells for optimal cellular or humoral immune response.

"We are delighted by the strong investor interest in this Series C financing which reflects the value created since our last round and speaks volumes to the potential of Selecta's platform and product pipeline," said Robert L. Bratzler, Ph.D., Executive Chairman of Selecta.

"This new financing will advance our breakthrough tSVP platform and take our lead product candidate through the initial clinical proof of concept evaluations," said Lloyd Johnston, Ph.D., Vice President of Pharmaceutical Research and Development of Selecta.

"Selecta's tSVP platform enables the development of targeted and fully integrated prophylactic and therapeutic vaccines and represents a truly revolutionary platform with the potential to leapfrog existing vaccine technologies," said Carl L. Gordon, Ph.D., founding General Partner of OrbiMed. "We believe Selecta's synthetic nanoparticle approach will have the potential to deliver safe and more effective vaccines for a broad range of diseases."

In connection with this financing, Dr. Gordon of OrbiMed will join the Board of Directors of Selecta, which is comprised of Robert Bratzler, Ph.D., Executive Chairman, Selecta Biosciences; Douglas Cole, M.D., General Partner, Flagship Ventures; Omid Farokhzad, M.D., Selecta Founder and Associate Professor, Harvard Medical School; Peter Hutt, Senior Counsel, Covington & Burling LLP; Robert Langer, Sc.D., Selecta Founder and Institute Professor, Massachusetts Institute of Technology; Amir Nashat, Ph.D., General Partner, Polaris Venture Partners; Aymeric Sallin, Managing Director and Founder, NanoDimension; and George Siber, M.D., Former Executive Vice President and Chief Scientific Officer, Wyeth Vaccines.

####

About Selecta Biosciences
Selecta Biosciences, Inc. is a biopharmaceutical company developing first-in-class synthetic nanoparticle vaccines using its proprietary targeted Synthetic Vaccine Particle (tSVPô) technology. The tSVP platform enables full-integration of the key vaccine components, antigens and adjuvants, for highly-effective targeting to immune cells to produce an optimal immune response. The tSVP vaccines mimics the structure of natural pathogens with regards to size, shape and the sequence of immunological information that it delivers to immune cells, thus harnessing the bodyís defense system to produce a robust immune response. The unique attributes of full-integration, targeting and natural structure conferred by the tSVP platform create synthetic nanoparticle vaccines that are engineered for unprecedented safety and efficacy. This novel approach enables expanded opportunities for tSVP vaccines, and the company is pursuing opportunities across a range of clinical applications, including infectious, metabolic, CNS and inflammatory diseases.

Selecta was founded in 2008 by three academic pioneers in the fields of nanotechnology and immunology: Professor Robert Langer (MIT), and Professors Omid Farokhzad and Ulrich von Andrian (Harvard Medical School). Selecta is backed by leading venture investors including, Polaris Venture Partners, Flagship Ventures, NanoDimension, OrbiMed Advisors and Leukon Investments. For more information please visit the company website at www.selectabio.com.

For more information, please click here

Contacts:
The Yates Network
Adriana Jenkins
617-744-1713

Copyright © Selecta Biosciences

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

How to maximize the superconducting critical temperature in a molecular superconductor: International team led by Tohoku University opens new route for discovering high Tc superconductors April 19th, 2015

Engineer improves rechargeable batteries with MoS2 nano 'sandwich' April 18th, 2015

Nanocomposites Play Effective Role in Production of Smart Fibers April 18th, 2015

Dais Analytic Corporation Appoints Eliza Wang to Board of Directors: Company's Newest Director Brings Expertise in Commercial and Legal Matters Both in the United States and China; Joins on the Heels of Successful Business Development Trade Mission to China April 18th, 2015

Investments/IPO's/Splits

Long Island Capital Alliance Announces Participants for Brookhaven National Laboratory Technology Transfer Capital Forum on May 8: Keynote Speaker Dr. Doon Gibbs, Director of Brookhaven National Laboratory April 16th, 2015

Graphenea embarks on a new era April 16th, 2015

Harris & Harris Group Portfolio Company OpGen Files Amended Registration Statement for Proposed Public Offering April 8th, 2015

Harris & Harris Group Reports Financial Statements as of December 31, 2014 and Posts Annual Letter to Shareholders on Website March 17th, 2015

Nanomedicine

Optical resonance-based biosensors designed for medical applications April 18th, 2015

Nanocomposites Play Effective Role in Production of Smart Fibers April 18th, 2015

Novel nanoparticles could save soldiers' lives after explosions April 15th, 2015

Nanoparticles at specific temperature stimulate antitumor response: Dartmouth researchers identify precise heat to boost immune system against cancer tumors April 14th, 2015

Announcements

How to maximize the superconducting critical temperature in a molecular superconductor: International team led by Tohoku University opens new route for discovering high Tc superconductors April 19th, 2015

Iranian Foodstuff, Agricultural Industries Welcome Nanotechnology Packaging Bags April 18th, 2015

Nanocomposites Play Effective Role in Production of Smart Fibers April 18th, 2015

Dais Analytic Corporation Appoints Eliza Wang to Board of Directors: Company's Newest Director Brings Expertise in Commercial and Legal Matters Both in the United States and China; Joins on the Heels of Successful Business Development Trade Mission to China April 18th, 2015

Appointments/Promotions/New hires/Resignations/Deaths

Dais Analytic Corporation Appoints Eliza Wang to Board of Directors: Company's Newest Director Brings Expertise in Commercial and Legal Matters Both in the United States and China; Joins on the Heels of Successful Business Development Trade Mission to China April 18th, 2015

Nanion Technologies Appoints James Costantin as Director of Customer Relations: Nanion is pleased to announce the appointment of Dr. James Costantin as Director of Customer Relations at Nanion Technologies Inc. March 31st, 2015

Nanofilm Appoints Senior Sales/Marketing Executives: Don Tecco, Director of Optical Sales, North America and Rex Talbott, Business Director Optical Products March 23rd, 2015

KIT Increases Commitment in Asia: DAAD Funds Two New Projects: Strategic Partnerships with Chinese Universities and Communi-cation Technologies Network February 22nd, 2015

Nanobiotechnology

Protein Building Blocks for Nanosystems: Scientists develop method for producing bio-based materials with new properties April 17th, 2015

Study shows novel pattern of electrical charge movement through DNA April 14th, 2015

UAB researchers develop a harmless artificial virus for gene therapy April 8th, 2015

Pavel Levkin Is Granted Heinz Maier-Leibnitz Prize April 8th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE